Gilead Sciences CFO sells shares worth $228,375
Andrew D. Dickinson, the Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), a prominent biotechnology company with a market capitalization of $113 billion and "GREAT" financial health ...
Gilead Sciences Inc. stock rises Wednesday, still underperforms market
Shares of Gilead Sciences Inc. GILD rallied 1.52% to $92.38 Wednesday, on what proved to be an all-around great trading ...
Gilead, US Settle Billion-Dollar Patent Feud Over Anti-HIV Drugs
Gilead Sciences Inc. and the federal government settled a patent-infringement case in which the US sought $1 billion from the ...
FiercePharma7h
Gilead's Kite taps longtime Amgen alum as new global commercial head
Kite Pharma is flying high with the addition of a new member to its senior leadership team. | Kite Pharma is flying high with ...
Gilead Sciences: Strategic Growth and Optimism Amidst Market Challenges
Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...
Gilead, LEO Pharma partner to develop programs for inflammatory diseases
Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...
BioSpace8h
JPM Day 3: AbbVie, Gilead, GSK and Dyne
AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...
Analysts Offer Insights on Healthcare Companies: Lyell Immunopharma (LYEL) and Gilead Sciences (GILD)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Lyell Immunopharma (LYEL – Research Report) ...